EU-Japan Biotech & Pharma Partnering Conference 2026

16 Sept – 5 Oct 2026 | Osaka, Japan

HomeAgenda
Register
Register
Register

ServiceUpdated on 5 September 2026

Human Stem Cell-Derived Cardiovascular Safety Testing

About

ABS is a pioneering biotechnology company specializing in human stem cell-derived cardiovascular models for predictive drug safety assessment and translational research.

Our platform enables pharmaceutical, biotechnology, and regenerative medicine companies to evaluate cardiac safety earlier and more accurately using human-relevant biology, helping to reduce development risk and improve decision-making throughout the drug development process.

We are seeking partnerships with organizations interested in:

  • Drug safety and cardiotoxicity assessment

  • Cardiovascular disease modeling

  • Translational and preclinical research

  • Regenerative medicine and cell therapy development

  • Co-development and joint research projects

  • Technology licensing and strategic collaborations

At the EU-Japan Biotech & Pharma Partnering event, we are particularly interested in connecting with Japanese and European companies looking to accelerate innovation in cardiovascular medicine through advanced human stem cell-derived technologies.

We welcome discussions with pharmaceutical companies, biotech innovators, CROs, academic institutions, and regenerative medicine organizations seeking reliable, human-relevant solutions for cardiovascular research and drug development.

Type

  • Development
  • Manufacturing

Applies to

  • Biotech and Lifescience